Nature Biotechnology
20, 780 - 784 (2002)
doi:10.1038/nbt0802-780
Orphan products—pain relief for clinical development
headachesChristopher-Paul Milne
Christopher-Paul Milne is assistant director,
Tufts Center for the Study of Drug Development, Tufts University,
Boston, MA 03301
christopher.milne@tufts.edu
As the cost of clinical development rises, and products take
longer to reach the market, the biotechnology industry may be wise to take a
closer look at orphan drug indications.
|
